Purchases are not available yet. You can browse the site and sign in.
Psilocybin Heart Conditions & the 5-HT2B Question · Microdosing College
Safety
Microdosing and the Heart: Psilocybin Heart Conditions and the 5-HT2B Question
By Microdosing College Editorial·Last updated September 12, 2026·8 min read
If you live with a heart condition, psilocybin heart conditions is exactly the right thing to be searching for before you go any further. Psilocybin reliably nudges up heart rate and blood pressure for a few hours, and there is a separate, more speculative worry about what repeated dosing might do to the heart's valves through a receptor called 5-HT2B. This article walks through what the evidence actually shows, what remains theoretical, and why reputable sources list significant heart disease as a reason not to microdose. It sits under our microdosing safety pillar — start there for the full picture.
Nothing here is medical advice or a green light. We never call any substance "safe," and a heart condition is one of the clearest situations where individualised clinical input — not a website — should decide the matter.
What psilocybin does to heart rate and blood pressure
The most consistent, best-documented cardiovascular effect of classic psychedelics is a temporary rise in heart rate and blood pressure during the acute window. As the UCSF Translational Research on Psychedelics program puts it, "the most common medical side effect of classic psychedelics is an elevation in blood pressure and heart rate" (Aragam, UCSF, 2022).
These changes are dose-dependent. In the peer-reviewed review Cardiovascular safety of psychedelic medicine by Agnieszka Wsół, controlled-study data showed that a sizeable 30 mg dose of psilocybin pushed heart rate to roughly 82 beats per minute (from about 74 at baseline) and systolic blood pressure to around 146 mmHg, with larger effects at higher doses (Wsół, 2023, Pharmacological Reports). It is worth being clear that those figures come from full therapeutic doses, not microdoses — a microdose is roughly a tenth of that amount, and its acute cardiovascular signal is correspondingly smaller and, in many people, hard to detect at all.
For a healthy cardiovascular system, a brief, modest rise in heart rate and pressure is usually unremarkable. The concern is not the average healthy person but the person whose heart cannot comfortably absorb even a small extra load — and that is the logic behind the contraindication.
Why heart disease is treated as a contraindication
Clinical trials of psilocybin have generally excluded people with cardiovascular disease, which is part of why we have so little direct safety data in this group (Wsół, 2023). Authoritative contraindication lists follow the same caution. UCSF names "severe cardiovascular disease including uncontrolled blood pressure, heart failure, coronary artery disease or previous heart attack or stroke" among the conditions in which classic psychedelics are contraindicated (Aragam, UCSF, 2022).
The reasoning is straightforward. A transient spike in heart rate and blood pressure is low-stakes for a healthy heart but potentially meaningful for someone with:
Uncontrolled or poorly managed high blood pressure, where an additional acute rise is undesirable.
Coronary artery disease or a prior heart attack, where increased cardiac demand carries more risk.
Heart failure, significant arrhythmias, or a history of stroke, where the margin for added strain is thinner.
Because this is precisely the population trials have left out, the honest position is one of caution by default: absence of evidence of harm is not evidence of safety. If any of the above describes you, the question is not which protocol to use — it is whether to involve a clinician at all, which our self-screener is designed to surface.
The 5-HT2B question: a theoretical concern for chronic dosing
Beyond the short-term blood-pressure story sits a more subtle, longer-horizon worry that specifically affects repeated dosing — the defining feature of microdosing. It centres on a serotonin receptor called 5-HT2B, which is densely expressed on the cells of the heart valves.
The concern is borrowed from a hard lesson in pharmacology. Several drugs that strongly activate 5-HT2B — most famously the diet drug fenfluramine (the "fen" in fen-phen), along with certain ergot medications and dopamine agonists — have been unequivocally linked to valvular heart disease when taken chronically. The proposed mechanism is that sustained 5-HT2B stimulation drives valve cells to overgrow, thickening and stiffening the valves; fenfluramine was withdrawn in 1997 after this pattern emerged (Roth, 2007, New England Journal of Medicine; see mechanism review, Hutcheson et al., 2011, Pharmacology & Therapeutics).
Psilocin (the active form of psilocybin) does bind the 5-HT2B receptor, and Wsół's review flags this as a reason for genuine caution about prolonged use, noting that drugs with high 5-HT2B affinity "have been unequivocally associated with valvular heart diseases" and that echocardiographic monitoring should be considered during and after prolonged psychedelic use — "particularly for microdosing regimens" (Wsół, 2023).
Two honest caveats matter here. First, this is theoretical for microdosing: there is no published study showing valve damage in people who microdose psilocybin, and the dose, frequency, and duration that would matter (if any) are unknown. Second, the drugs that caused valvulopathy were taken daily for months or years at meaningful concentrations — a pattern most microdosing schedules, with their built-in off-days, do not match. The point is not that valve damage is proven, but that the receptor biology gives a plausible reason to avoid open-ended daily dosing and to take the chronic-use question seriously rather than dismiss it.
Practical takeaways and where to go next
If you take away one thing: a heart condition moves microdosing from "educate yourself and decide" into "do not proceed without a clinician." Concretely:
Significant cardiovascular disease is a contraindication. Uncontrolled hypertension, coronary artery disease, heart failure, serious arrhythmia, or a history of heart attack or stroke are reasons not to microdose without medical oversight.
Acute effects are real but usually modest at microdoses — the larger heart-rate and blood-pressure numbers come from full doses, not tenths of one.
The 5-HT2B valve concern is theoretical, not demonstrated, but it is a sound argument against indefinite daily dosing and a reason researchers call for cardiac monitoring in long-term use.
Check your medications too. Some heart and blood-pressure drugs, and many psychiatric medications, interact with psilocybin — run through our drug interactions checklist before anything else.
If you are pregnant or breastfeeding, separate cautions apply on top of any cardiac ones — see microdosing during pregnancy and breastfeeding. To understand how these risks fit together, return to the microdosing safety hub, browse the studies in our research library, and use the self-screener before making any decision. If you are worried about chest pain, palpitations, or your heart right now, contact local emergency services — see our crisis resources.
This article describes what is known and what is uncertain so that an informed adult can make a responsible, legal choice. It is not a recommendation to take any substance, and it cannot replace assessment by a clinician who knows your heart.
Frequently asked
Can I microdose psilocybin if I have a heart condition?+
Significant cardiovascular disease — uncontrolled high blood pressure, coronary artery disease, heart failure, serious arrhythmia, or a prior heart attack or stroke — is widely treated as a contraindication. Psilocybin temporarily raises heart rate and blood pressure, and trials have excluded cardiac patients, so there is little safety data. Do not proceed without a clinician; start with our self-screener.
How much does psilocybin raise heart rate and blood pressure?+
At full therapeutic doses, controlled data cited by Wsół (2023) showed a 30 mg dose raising heart rate to around 82 bpm and systolic pressure to about 146 mmHg, dose-dependently. A microdose is roughly a tenth of that, so its acute cardiovascular effect is much smaller and often hard to detect — but it is not zero.
What is the 5-HT2B valve concern with microdosing?+
5-HT2B is a serotonin receptor on heart-valve cells. Drugs that strongly and chronically activate it — like the withdrawn diet drug fenfluramine — have been linked to valve damage. Psilocin binds 5-HT2B, so there is a theoretical worry about long-term frequent dosing. It has not been demonstrated in microdosers, but it argues against open-ended daily use.
Is occasional microdosing safer for the heart than daily dosing?+
No substance is simply 'safe,' and we can't promise that. But the 5-HT2B valve concern is specifically about sustained, chronic activation, and the drugs that caused valvulopathy were taken daily for months or years. Most microdosing schedules include off-days. That doesn't make it risk-free, especially if you already have heart disease.
Do my heart medications interact with psilocybin?+
Some can. Blood-pressure and heart drugs, plus many psychiatric medications, may interact with psilocybin in ways that affect the cardiovascular system or other risks. Review our drug interactions checklist and discuss your full medication list with a clinician before considering anything.
This guide is general educational information about microdosing, not medical advice and not a recommendation to use any substance. It can't account for your personal health. If you take medication or live with a mental-health condition, speak with a qualified professional before making any decision.
